A Phase Ib Dose Escalation Study of BCL201 in Combination With Idelalisib in Patients With Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL)
Phase of Trial: Phase I
Latest Information Update: 07 Jul 2017
At a glance
- Drugs Servier 1 (Primary) ; Idelalisib
- Indications Follicular lymphoma; Mantle-cell lymphoma
- Focus Adverse reactions
- Sponsors Novartis
- 30 Jun 2017 Planned End Date changed from 21 Jun 2019 to 22 Jun 2019.
- 10 Jun 2017 Biomarkers information updated
- 17 Mar 2017 Planned End Date changed from 18 Apr 2018 to 21 Jun 2019.